IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 2, Issue 1, December 2022
Impact Factor: 6.252

Pharmacokinetics and Cognitive Side Effcets of Cannabidiol In Adult Patients

Miss. Akanksha N. Mote, Miss. Pratiksha B. Bhise, Miss. Rasika D. Chavan, Miss. Prapti P. Patil, Manohar D. Kengar
Nootan College of Pharmacy, Kavathe Mahankal, Maharashtra, India

Abstract: *Nowadays, there's a great interest in the possible medical use of cannabidiol(CBD), anon-intoxicating cannabinoid. Productive pharmacological investigation on CBD passed in the 1970s and boosted freshly with multiple discoveries about the Endocannabinoid System. The World Health Organization(WHO) Considers registering cannabis and cannabinoids. CBD use around the world is developing for conditions that need scientific proof of the medicine's efficacacy. The effect of cannabinoids on anesthesia is mentioned compactly. Important Advances have taken place in cannabinoid study over the last many times and have conducted to the discovery of new Ligands. The possible clinical operations of these ligands and the direction of coming study are agitated.*

Background: *Cannabidiol is being coursed as a medicinal treatment for multiple conditions, generally by oral delivery. Creature studies suggest oral bioavailability is low, but literature in humans isn't sufficient.(1)*

Keywords: Pharmacokinetics

I. INTRODUCTION

Two separate cannabis receptors have been identified (CB1 and CB2), which were cloned in 1990 and 1993, respectively .Both receptors are coupled to G proteins and their activation leads to an inhibition of Adenyl cyclase, decreased production of cAMP and Modulation of the ion channel activity. At the cellular Level, cannabinoids act through CB receptors to Hyperpolarize neurones by closing voltage-dependent Calcium channels and by activating potassium channels . Cannabidiol (CBD) is a constituent of Cannabis sativa and constitutes up to 40 of the passages of the factory.(2) still, CBD attention are largely variable and depend on the raising conditions, the different phenotypes of lawless cannabis, and on the part of the factory deconstructed.(3)(4). Δ9- tetrahydrocannabinol(THC) was shown to be the primary psychoactive mixture in cannabis(marijuana) (5).The Cannabis sativa factory contains added than a hundred phyto- cannabinoid mixtures, Including thenon-psychotomimetic mixture cannabidiol(CBD) (6). CBD has attracted significant interest due to itsanti-inflammatory, anti-oxidative andanti-necrotic defensive goods, as well as showing a good safety and tolerability substance in humans.(10), and Its structure was associated 23 times(11). Since also, a considerable number of published papers have dealt with its chemistry, biochemistry, pharmacology and clinical goods. By the time 2000, the primary examination contents regarding possible medicinal goods of CBD were related to its antiepileptic, relaxing, anxiolytic and antipsychotic conditioning(13)(14). Also, CBD is generally used as a Popular food supplement in a variety of formats for a range of complaints(8). It's estimated that the CBD request will grow to$2.1 billion in the US request in consumer deals by 2020 (8). CBD is also being followed in Clinical trials in Parkinson's condition, Crohn's complaint, society anxiety complaint, and schizophrenia(9). These studies have raised the possibility of remedial goods of CBD for different conditions, including mania, cerebral ischemia, Diabetes, inflammatory conditions, nausea and psychiatric diseases.(15). From previous examinations including animal studies, the oral bioavailability of CBD has been shown to be very low(13 – 19)(16). Tube and brain attention are cure-dependent in creatures, and bioavailability is increased with various lipid statements(17).

However, some side goods have been reported For CBD, but primarily in vitro or in animalstudies. They include differences of cell viability, reduced fertilization capacity, and inhibition of hepatic medicine metabolism and medicine transporters(e.g., p- glycoprotein).(18) thus, another natural studies have to be conducted to see if these goods also

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 2, Issue 1, December 2022
Impact Factor: 6.252

happen in humans. In these studies, a large enough number of subjects have to be registered to assay long- term safety phases and CBD possible relations with other substances. (7)

II. PHARMACOKINETICS OF CANNABINOIDS

The pharmacokinetics of Cannabinoids are reviewed by Agurell et al(1986) and Maykut(1985) and others. About 50 of the THC in a joint of herbal cannabis is inhaled in mainstream bank; nearly all of this is absorbed through the lungs, rapidly enters the bloodstream and reaches the brain within minutes. Goods are distinguishable within alternate and completely apparent in a many twinkles. The onset of effect is delayed(0.5- 2hours) but the duration is prolonged because of continued slow immersion from the inside. Once absorbed, THC and other Cannabinoids are rapidly distributed to all other tissues at rates dependant on the blood stream. Because they're extremely lipid soluble, Cannabinoids accumulates in adipose tissues, reaching peak attention in 4- 5 days. They're also slowly released back into other body chambers, including the brain. Because of the insulation in fat, the tissue elimination half- life of THC is about 7 days and complete elimination of a single cure may take up to 30 days (Maykut, 1985). High concentration are reached in neocortical, limbic, sensitive and motor areas. Cannabinoids are metabolised in the liver. A major metabolite is 11- Hydroxy- THC which is maybe more concentrated than THC itself and may be responsible for some of goods of cannabis. Because of the pharmacokinetics of Cannabinoids – both the insulation in fat and the presence of active metabolites- there is really poor relationship between tube or urine attention and degree of cannabinoid- induced intoxication.Le delta-9-tétrahydrocannabinol (Δ-9-THC) est le star component Psychoactif du cannabis (marijuana).

Most available information on the pharmacokinetics of cannabinoids certains to Δ 9- THC. Other cannabinoids, among them the Phytocannabinoids cannabidiol(18) and cannabidiol(19) and the synthetic secondary dexanabinol(20) show similar kinetic profiles as the major psychotropic constituent of cannabis. Kinetics of cannabinoids are principally important the same for female and male humans(21).

The pharmacokinetics of other cannabinoids resembles the kinetics of THC with regard to plasma course, final half-lives and other parameters. These will be reviewed compactly for the natural cannabinoids CBD and CBN, for nabilone, a synthetic 9- ketocannabinoid and psychotropic derivative of cannabinol available on prescription in several countries, and for dexanabinol, anon-psychotropic analog of Δ 8- THC under clinical research. Average systemic bioavailability of inhaled CBD in a group of cannabis users was 31(range 11- 45).(22) The plasma pattern was similar to that of THC with high situations of about 100 ng/ ml within minuetsafter smoking and fast drop to a concentration of about10ng/ ml after one hour. After oral administration of 40 mg CBD, the tube course over 6 h was in the same range as the course after 20 mg THC(23). Daily oral doses of 10 mg/ kg CBD per day for 6 weeks in cases with Huntington's disease resulted in mean daily Plasma situations of5.9-11.2 ng/ ml(24). The distribution volume was about 30 L/ kg, lesser than for THC. (22) In rats entering intravenous THC and CBD(1 mg/ kg body weight all), brain concentrations of unchanged CBD were advanced than that of THC 5 minutes after administration(25).The tube concurrence classified from 960 to 1560 ml/min.An average terminal half- life of 24 h(range 18- 33 h) was determined after intravenous injection of 20 mg during an observation period of 72 h(22). Average systemic bioavailability after smoking 19 mg CBN was 26 (range 8- 65), analogous or kindly developed than the values for THC. The volume of distribution was determined to 23 L/ kg(19). The apparent terminal half lives for CBN were 17 h and 29 h after intravenous administration and smoking individually (19). Metabolic patterns in humans were analogous to THC with a main attack at C- 11(26). Excretion was slower with about 8 excluded with urine and 35 excreted in feces within 72 h.(26).

III. METHODS

This review was conducted using reports reacquired from Web of Science, Scielo and Medline. The keywords searched Were " cannabinoids ", " cannabidiol " and " side possession. " No Time limits were charged on the quest criteria.

A literature hunt, from beginning to January 2019, was Performed on PubMed, EMBASE, and capital(Cochrane Central Register of Controlled Trials) using the key- Words cannabidiol Epidiolex, adverse or lateral things, adverse responses or events, safety, complications, toxin, and Toxicology. This regular review was conducted in agreement with the Preferred Reporting details for Methodical Reviews 126 and Meta- Analyses(PRISMA) guidelines and reporting criteria(41).

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 2, Issue 1, December 2022
Impact Factor: 6.252

3.1 Search Strategy

The systematized review was carried out in agreement with PRISMA(Preferred Reporting points for Methodical Reviews and Meta- Analyses) guidelines (42). A methodical Hunt of PubMed and EMBASE(including MEDLINE) was Conducted to re-collect all papers reporting pharmacokinetic Data of CBD in humans. Search terms included CBD, Cannabidiol, Epidiolex, pharmacokinetics, Cmax, tube attention, tube places, half- life, peak attention, immersion, bioavailability, AUC, Tmax, Cmin, and apparent Volume of distribution. Vital words included cannabidiol, cognition, cognitive impairment, memory and education. No restrictions were applied to Type of study, publication time, or language. The quests Were carried out by 14 March 2018 by two independent investigators. For sample, the hunt strategy for Medline was(cannabidiol AND cognition) or (cannabidiol AND cognitive AND impairment). The reference lists of eligible studies were also screened to identify another studies.

3.2 Eligibility Criteria

The titles and abstracts of recaptured studies were examined by two independent experimenters, and unhappy papers were rejected. Addition criteria were as follows an original, peer- reviewed paper that involved administration of CBD to humans, and included at least one pharmacokinetic dimension as listed in the hunt strategy.Studies eligible for addition in this methodical review must have assessed the effect of CBD on cognitive disciplines applicable to schizophrenia(as defined in MATRICS) and must have been published in English. All studies were originally screened by title and abstract to insure that only empirical studies related to the content were included. Original investigation papers that passed the original webbing were reviewed in full textbook.

3.3 Data Acquisition

The included papers were anatomized, and the following data extracted sample size, gender, administration route of CBD, source of CBD, cure of CBD, and any pharmacokinetic details.Where available, tube mean or standard C -max (ng/ mL) were plotted against CBD cure(mg). Also, mean or median T -max and range, and mean or median area under the curvature(AUC0 – t) and SD were put up against CBD cure(mg). The source supplier of the CBD was alsorecorded.All studies were assessed for quality using an Amended performance of the National Institute for Health(NIH), National Heart, Lung and Blood Institute, Quality Assessment Tool for Before- After(Pre-Post) Studies with No Control Group(National Institute for Health (43) A sample size of ≤ 10 was Considered poor, between 11 and 19 was considered fair, (44).

3.4 Protocol and Registration

This review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA) , and the review protocol was registered before hand (45).

3.5 Inclusion and Exclusion Criteria

The following inclusion and exclusion criteria were developed prior to screening:

A. Inclusion

1. Medical cannabis in a controlled setting with information about strength and dose of CBM, and with Cognitive testing at baseline before treatment and With at least one follow-up testing.
2. Studies only.
3. Own case-control (baseline, repeated measures Design, longitudinal study, cross-over design).
4. Baseline test while not under treatment and/or the
5. Influence of cannabis or other psychoactive drugs.
6. Re-test conducted while under cannabis treatment And/or the infuence.
7. Measures from at least one recognised cognitive test.

B. Exclusion

1. Studies on abuse and/or abstinences.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 2, Issue 1, December 2022
Impact Factor: 6.252

2. Populations with severe neurodegenerative brain diseases and cancer-related pain conditions.
3. Severe psychiatric diseases, such as schizophrenia or Psychosis.
4. Under the age of 18

IV. RESULT AND DISCUSSION

The aim of this study was to review and analyse all available data on CBD in humans. Only 8 publications reported PK parameters after administering CBD on its own, and the others were in combination with THC/ cannabis. Only 1 study reported the bioavailability of CBD in humans (31 following smoking). Overall, considerable variation was observed between studies, although they were very heterogeneous, and further work iswarranted.This is an exciting time for CBD research and medicine.Epidiolex, containing 98% CBD, was approved by the FDA for the treatment of intractable epilepsy in patients with Dravet's or Lennox-Gastaut syndromes, showing that a plant extract containing primarily CBD can provide the reproducibility needed for pharmacotherapies.

There's active in vitro and preclinical research into the mechanisms of action of CBD in efforts to better understand its pharmacodynamics and pharmacokinetics and therapeutic potential. Clinical research is proceeding for multiple indications for CBD in well- designed, randomized, placebo- controlled clinical trials, by a variety of routes of administration. Pharmaceutical companies pursue synthetic CBD and plant extracts as CBD sources. CBD may provide a new approach as a stand-alone drug and as an adjunct to other medications for unmet clinical needs.

The most important consideration is whether or not there's sufficient scientific data that CBD is efficacious in treating a patient's disease or condition. The field is changing rapidly, but proof of efficacy is limited currently to CBD as ananti-epileptic. A second critical factor is dose, route, and frequency of administration. In many of the preclinical studies, much higher CBD concentrations were administered. For example, many of the cardiovascular, hepatocellular damage, inhibition of P450 systems, hormone changes, decreased fertility, alterations of in vitro cell viability, and reduced P-glycocoprotein activities effects occurred at doses of> 200 Mg/ kg/ day (27). Drug interactions are an important issue to be precisely considered when defining CBD. CBD is frequently added to a authority of other specifics, especially otheranti-epileptics and the eventuality for medicine- medicine relations could lead to serious health consequences. In vitro and in vivo data suggest that CBD interacts with medicinals, specifically drug metabolized by theliver .Drug- drug relations with CYP1A2 substrates(theophylline, caffeine), CYP2B6 substrates(bupropion, efavirenz), UGT1A9(diflunisal, propofol, fenofibrate), UGT2B7(gemfibrozil, lamotrigine, morphine, lorazepam), and clinically significant relations with CYP2C8 and CYP2C9(phenytoin) substrates do whenco-administered with Epidiolex(28).

Two of the common AEs after CBD administration are doziness and sedation(28, 29, 30, 31). These goods are cure-related and potentiated byco-administration of theanti-epileptic medicines including clobazam and valproate, and other CNS depressants(including alcohol). Cases should be advised that their capability to drive or operate ministry could be bloodied while under CBD treatment. The former has been considerably studied and is known to affect cognitive functions(32). L whereas the ultimate has not been studied as considerably and therefore is the subject of this review. Principally, we want to know if we can treat cases with CBM without negatively affecting, or affecting to a minimum degree, their Cognitive functions and hence their diurnal conditioning. This includes examining implicit goods after conclusion.(33) which set up bettered speed memory and administrative functioning after pullout from long- term use of CBMs, indicating that stable long- term use may negatively impact cognitive functioning. The results should be interpreted with caution, since no bedazzling was applied, and the sample size was small, reflected in a weak standing on the EPHPP. They included studies are veritably different in factors similar as cure, duration, type of cannabis, route of administration, previous history and other medicine(s) used. All of these are factors that presumably play a crucial part in examining implicit adverse goods on cognition. The diversity makes any possible comparisons across studies veritably limited and hence hamper our understanding. There seems to be a trend towards using Sativex in further controlled settings and invariant case groups. This will greatly enhance the substantiation. Still, allowed should be given as to how studies can incorporate previous use and other medicine use in the design, as this reflects the real- life situation of numerous cases.(32) our results indicate that the impact of CBMs on cognitive functioning is minimum as long as the boluses of THC are low to moderate. Unfortunately, the studies are too divergent to specify the outside cure of THC permitted before cognition is negatively affected. still, among cases with neuropathic pain.(34, 35) indicate that treatment with a THC cure below 19 mg didn't affect cognition significantly else from the placebo group. The

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 2, Issue 1, December 2022
Impact Factor: 6.252

results of the present review don't reflect the high number of adverse events(OR5.67) in relation to cognition and attention disturbances ' reported in the meta analysis by socks(36). This may be due to the fact that that(36) was grounded on tone- reported symptoms, which is extensively different from objective test results on recognised neuropsychological tests administered in a controlled setting. This is an important finding, since bloodied cognitive functioning associated with CBMs may affect in cases rejecting the treatment on false demesne due to fear of reduced cognitive functioning. But again, the diversity of cognitive tests used across studies without population morals, combined with the extensively different study designs, patient populations and type of CBMs used, make it insolvable to draw definite conclusions about the impact of CBMs on cognitive functioning.(36).

V. CONCLUSION

Several studies suggest that CBD is well permitted and safe in humans at high doses and with habitual use. still, In vitro and in vivo studies showed implicit medicine metabolism relations, cytotoxicity, and dropped receptor exertion. This data highlights the need for careful monitoring of CBD use in humans, especially when CBD is used in clinical practice, similar as in the treatment of psychiatric diseases or as an option for drug abuse treatment(37). CBD has a half- life of 24 hours on average, with a two fold in the time noted by i.v. route and normal of 31 hours by steam route. CBD is cleared from a tube at rates between 960 and 1560 ml/ min and its distribution volume is estimated to be around 30L/ kg.(38).

Due to large diversity and methodological limitations. Across studies, it isn't possible to make any definite conclusion about the impact of CBMs on cognitive functioning. still, the maturity of high- quality substantiation suggests that the negative impact of CBMs on cognitive Functioning is small, as long as the doses of THC are low to moderate. On the other hand, long- term use of CBMs may still negatively impact cognitive functioning. The cognitive disciplines substantially set up to be negatively affected by CBMs are attention/ attention and memory. No substantiation of this review indicates that CBD oppressively influences cognitive functioning, at least not when taking the doses applied in the included studies. The implicit Positive effect of CBMs on cognitive functioning may be due to practice goods or intermediated by relief of other medical symptoms, similar as pain, depression or sleep problems. Further high- quality longitudinal placebo- controlled studies assessing the implicit long- term impact of CBMs on cognitive functioning are demanded. Especially abecedarian is the focus on CBMs for specific medical conditions with control for cure and type of CBMs, as well as the use of validated cognitive tests. With regard to distribution and redivision, cannabinoids cause several problems in forensic science. It's difficult or impossible to assess the actual degree of impairment of drivers from cannabinoid situations in body Fluids or to estimate the time of the last consumption. In discrepancy to the hydrophilic alcohol, cannabinoids are lipophilic and there's only weak co-relation on between THC situations in the effect cube(central nervous System) and THC situations in blood or other body fluids. thus, it seems reasonable to assess factual impairment with other means, e.g., responses of the eye pupils to light. Amplitude, compression speed and dilation speed of the pupils following a defined light encouragement show a cure dependent geste

with minimal goods in the first hour after smoking cannabis and a gradational decline later(38). Since several studies on CBD involve creatures, the different metabolic biographies between species must be taken into account. CBD metabolism seems to follow the same pathways across species, although variations may do, similar as the involvement of different enzymes leading to different positions of hydroxylated composites, or still the registration of a different type of sugar(or further than one) during conjugation, which could explain some slight differences in CBD goods or in metabolites between species (39) .This review could substantiate and expand the findings of Bergamaschi etal. about CBD favorable safety profile(40). The increased conformation of 11- OH- THC with oral use compared to inhalation is frequently made responsible for stronger psychotropic goods of oral Cannabinoids. But it seems that this metabolite has a analogous pharmacological profile as THC in man and binds to the CB1 receptor, making it unclear how this metabolic difference may cause differences ineffects.There seems to be no applicable difference between single THC and whole Factory cannabis taken both orally and inhaled with regard to psychotropic and other private goods(41), supporting the view that the differences in scheduling cannabis and THC(dronabinol) in the anesthetics acts of numerous countries are grounded more on political than on pharmacological grounds .

In conclusion, possible factors contributing to CBD AEs are CBD potency, route of administration (vaporized, transdermal, oral), concurrent licit and illicit drug use, and drug-drug interactions.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 2, Issue 1, December 2022
Impact Factor: 6.252

REFERENCES

[1]. Systematic Review on the pharmacokinetics of Cannabidiol in humans .Sophie A. Millar 1*, Nicole L. Stone1, Andrew S. Yates 2 and Saoirse E. O'Sullivan1

[2]. Grlie L. A comparative study on some chemical and biological characteristics of various samples of cannabis resin. Bull Narcot1976; 14: 37–46

[3]. Mehmedic Z, Chandra S, Slade D, et al. Potency trends of 9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 2010; 55: 1209-17.

[4]. Perez-Reyes M, Timmons MC, Davis KH, Wall ME. A comparison of the pharmacological activity in man of intravenously administered delta-9-tetrahydrocannabinol, cannabinol and cannabidiol. Experientia 1973; 29: 1368-9.

[5]. Gaoni, Y.; Mechoulam, R. Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc., 1964, 86, 1646-1647. [http://dx.doi.org/10.1021/ja01062a046].

[6]. Izzo, A. A., Borrelli, F., Capasso, R., Di Marzo, V., and Mechoulam, (2009). Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol. Sci. 30, 515–527.Doi: 10.1016/j.tips.2009.07.006

[7]. Bergamaschi, M. M., Queiroz, R. H., Zuardi, A. W., and Crippa, J. A. (2011). Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr. Drug Saf. 6,237–249. Doi: 10.2174/157488611798280924.

[8]. Hemp Business (2017). Hemp Business Journal. State of Hemp Market Report.

[9]. Crippa, J. A., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F.L., Martin-Santos, R., et al. (2011). Neural basis of anxiolytic effects of Cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.J. Psychopharmacol. 25, 121–130. Doi: 10.1177/0269881110379283.

[10]. Adams R, Hunt M, Clark JH. Structure of cannabidiol, a product Isolated from the marihuana extract of Minnesota wild hemp. J Am Chem Soc 1940; 62: 196-200.

[11]. Mechoulam R, Shvo Y. The structure of cannabidiol. Tetrahedron 1963; 19: 2073-8.

[12]. Cunha JM, Carlini EA, Pereira AE, et al. Chronic administration of Cannabidiol to healthy volunteers and epileptic Pharmacology 1980; 21: 175-85.

[13]. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006; 39(4): 421-drug. Braz J Med Biol Res 2006; 39(4): 421-9.

[14]. Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug With wide spectrum of action. Rev Bras Psiquiatr 2008; 30(3): 271-80.

[15]. Mechoulam, R., Parker, L. A., and Gallily, R. (2002). Cannabidiol: an overview of some pharmacological aspects. J. Clin. Pharmacol. 42, 11S−19S.doi: 10.1002/j.1552-4604.2002.tb

[16]. Zgair, A., Wong, J. C., Lee, J. B., Mistry, J., Sivak, O., Wasan, K. M., et al. (2016). Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. Am. J. Transl. Res.8, 3448–3458, 3448–3Bergamaschi MM, Queiroz RH, Zuardi AW, et al. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf. 2011;6:237–24237–249.

[17]. Samara, E., M. Bialer, and R. Mechoulam. 1988. Pharmacokinetics of cannabidiol in Dogs. Drug Metab Dispos 16(3):469-72.

[18]. Johansson, E., A. Ohlsson, J.E. Lindgren, S. Agurell, H. Gillespie, and L.E. Hollister.1987. Single-dose kinetics of deuterium-labelled cannabinol in man after intravenous administration and smoking. Biomed Environ Mass Spectrom 14(9):495-9.

[19]. Brewster, M.E., E. Pop, R.L. Foltz, S. Reuschel, W. Griffith, S. Amselem, and A. Biegon.1997. Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. Int J Clin Pharmacol Ther 35(9):361-5.

[20]. Wall, M.E., B.M. Sadler, D. Brine, H. Taylor, and M. Perez-Reyes. 1983. Metabolism, Disposition, and kinetics of delta-9-tetrahydrocannabinol, in men and women. Clin Pharmacol Ther 34(3):352- Pharmacol Ther 34(3):352-63.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 2, Issue 1, December 2022
Impact Factor: 6.252

[21]. Ohlsson, A., J.E. Lindgren, S. Andersson, S. Agurell, H. Gillespie, and L.E. Hollister 1984. Single dose kinetics of cannabidiol in man. In The Cannabinoids: Chemical,: Pharmacologic, and Therapeutic Aspects, edited by S. Agurell, W.L. Dewey, and R. Willette. New York: Academic Press.

[22]. Agurell, W.L. Dewey, and R. Willette. New York: Academic PAgurell, S., S. Carlsson, J.E. Lindgren, A. Ohlsson, H. Gillespie, and L. Hollister. 1981.Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass Fragmentography. Experientia 37(10):1090.

[23]. Consroe, P., J. Laguna, J. Allender, S. Snider, L. Stern, R. Sandyk, K. Kennedy, and K. Schram. 1991. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 40(3):701-8.

[24]. Alozie, S.O., B.R. Martin, L.S. Harris, and W.L. Dewey. 1980. 3H-delta 9-Tetrahydro-cannabinol, 3H-cannabinol and 3H-cannabidiol: penetration and regional distribution in rat brain. Pharmacol Biochem Behav 12(2):217-21.

[25]. Wall, M.E., D.R. Brine, and M. Perez-Reyes. 1976. Metabolism of cannabinoids in man.In Pharmacology of Marihuana, edited by M.C. Braude, S.

[26]. Rosenkrantz, H.; Fleischman, R.W.; Grant, R.J. Toxicity of short-term administration of cannabinoids to rhesus monkeys. Toxicol. Appl. Pharmacol., 1981, 58, 118-1Appl. Pharmacol., 1981, 58, 118-131.

[27]. Greenwich Biosciences. Epidiolex, full prescribing information.https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/21036 5lbl.pdf (Accessed 12 March, 2019).

[28]. Thiele, E.A.; Marsh, E.D.; French, J.A.; Mazurkiewicz-Beldzinska, M.; Benbadis, S.R.; Joshi, C.; Lyons, P.D.; Taylor, A.; Roberts, C.; Sommerville, K.; GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 2018, 391, 1085-1096.

[29]. Devinsky, O.; Marsh, E.; Friedman, D.; Thiele, E.; Laux, L.; Sulli-Van, J.; Miller, I.; Flamini, R.; Wilfong, A.; Filloux, F.; Wong, M.; Tilton, N.; Bruno, P.; Bluvstein, J.; Hedlund, J.; Kamens, R.; Ma-Clean, J.; Nangia, S.; Singhal, N.S.; Wilson, C.A.; Patel, A.; Cilio, M.R. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol., 2016, 15, 270-278.

[30]. Neale, M. Efficacy and safety of cannabis for treating children with refractory epilepsy. Nurs. Child. Young People, 2017;

[31]. Landrigan J, Bessenyei K, Leitner D, Yakovenko I, Fisk JD, Prentice JL. A systematic review of the efects of cannabis on cognition in people with multiple sclerosis. Mult Scler Relat Disord. 2022;57:1033multiple sclerosis. Mult Scler Relat Disord. 2022;57:103338 .

[32]. Feinstein A, Meza C, Stefan C, Staines RW. Coming of cannabis: a cognitive and magnetic resonance imaging study in patients with multiple Sclerosis. Brain. 2019;142(9):2800–12 .

[33]. Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008;9(6):506–2neuropathic pain. J Pain. 2008;9(6):506–21.

[34]. Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose Vaporized cannabis significantly improves neuropathic pain. J Pain. 2013;14(2):136–48.

[35]. Stockings E, Campbell G, Hall WD, Nielsen S, Zagic D, Rahman R, et al. Cannabis and cannabinoids for the treatment of people with chronic Non cancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain. 2018;15 .

[36]. Russo EB. Taming THC: potential cannabis synergy and Phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 2011; 163(7): 1344-6 2011; 163(7): 1344-64.

[37]. Kelly, T.H., R.W. Foltin, C.S. Emurian, and M.W. Fischman. 1993. Performance-based testing for drugs of abuse: dose and time profiles of marijuana, amphetamine, alcohol,and diazepam. J Anal Toxicol 17(5):264-72 .

[38]. Harvey DJ, Samara E, Mechoulam R. Comparative metabolism of cannabidiol in dog, rat and man. Pharmacol Biochem Behav. 1991; 40(3): 523-340(3): 523-32.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 2, Issue 1, December 2022
Impact Factor: 6.252

[39]. Bergamaschi MM, Queiroz RH, Zuardi AW, et al. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf. 2011;6:237–249.

[40]. Wachtel, S.R., M.A. ElSohly, S.A. Ross, J. Ambre, and H. De Wit. 2002. Comparison of the subjective effects of delta(9)-tetrahydrocannabinol and marijuana in humans.Psychopharmacology 161(4):331-9.

[41]. Moher D, Liberati A, Tetzlaff J, Altman DG, Grp P, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Brit Med J. 2009;339(7716):332-6.

[42]. Moher, D., Liberati, A., Tetzlaff, J., and Altman, D. G. (2009). Preferred reporting Items for systematic reviews and meta-analyses: the PRISMA statement.Ann. Int. Med. 151, 264–269, w64. Doi: 10.7326/0003-4819-151-4-20090818000135 .

[43]. National Institute for Health (2014). National Lung and Blood Institute Quality Assessment Tool for Before-After (Pre-Post) Studies with No Control Group.

[44]. arons, L., and Graham, G. (2006). Sample size calculations Based on generalized estimating equations for population pharmacokinetic Experiments. J. Biopharm. Stat. 16, 135–150. Doi: 10.1080/10543400500508705 .

[45]. Moher D, Liberati A, Tetzlaf J, Altman DG, The PG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoSMed.2009;6(7):e1000097.

[46]. A Systematic Review on thePharmacokinetics of Cannabidiol inHumans -Sophie A. Millar 1, Nicole L. Stone1, Andrew S. Yates 2 and Saoirse E. O'Sullivan1 ;published: 26 November 2018 .

[47]. An Update on Safety and Side Effects of Cannabidiol:A Review of Clinical Data and Relevant Animal Studies Kerstin Iffland and Franjo Grotenhermen,2017 .

[48]. A systematic review of the effect of cannabidiol oncognitive function: relevance to schizophrenia ,2017 ; Ashlrigh L. Ossborne , Nadia Solowij , Katrina Weston – Green .

[49]. Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent , Mateus Machado Bergamaschi1,2, Regina Helena Costa Queiroz, José Alexandre S. Crippa, and Antonio Waldo Zuardi ,current drug safety ,2011 ,6 ,000-000.

[50]. The efect of medical cannabis on cognitive functions: a systematic review ;Anders Wieghorst, Kirsten Kaya Roessler, Oliver Hendricks, and Tonny Elmose ,Andersen; 2022

[51]. Pharmacology and effects of cannabis :a brief review ;C. HEATHER ASTHION .

[52]. Clinical pharmacokinetics of cannabinoids ;Franjo Grotenhermen ;January 2003.

[53]. Human Pharmacokinetics and Adverse effects of Pulmonary and Intravenous THC-CBD Formulations .2018;Pascale Meyer, Manuela Langos ,Rudolf Brenneisen .